Negative alterations of mitochondria are known to occur in heart failure (HF). This study investigated the novel mitochondrial-targeted therapeutic agent elamipretide on mitochondrial and supercomplex function in failing human hearts ex vivo. Freshly explanted failing and nonfailing ventricular tissue from children and adults was treated with elamipretide. Mitochondrial oxygen flux, complex (C) I and CIV activities, and in-gel activity of supercomplex assembly were measured. Mitochondrial function was impaired in the failing human heart, and mitochondrial oxygen flux, CI and CIV activities, and supercomplex-associated CIV activity significantly improved in response to elamipretide treatment. Elamipretide significantly improved failing human mitochondrial function.
Authors
Chatfield, Kathryn C; Sparagna, Genevieve C; Chau, Sarah; Phillips, Elisabeth K; Ambardekar, Amrut V; Aftab, Muhammad; Mitchell, Max B; Sucharov, Carmen C; Miyamoto, Shelley D; Stauffer, Brian L
Keywords
ADP, adenosine diphosphateBN-PAGE, blue native polyacrylamide gel electrophoresisC, mitochondrial respiratory complexFCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazoneHF, heart failureRCR, respiratory control ratioSC CCF, supercomplex coupling control factorheart failurehigh-resolution respirometrymitochondrial-targeted compoundssupercomplex